Clinical Trial Update: TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients [Phase 3]

View source ↗

Summary

A clinical trial update indicating that Shenzhen TargetRx's investigational drug TGRX-678 is planned for a Phase 3 study in Chinese patients with chronic myeloi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• TGRX-678

Snippet

Sponsor: Shenzhen TargetRx Co., Ltd. | Conditions: Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase | Phase 3 | Status: NOT_YET_RECRUITING